NCBiotech News

Target RWE, a clinical data company based in Durham, has acquired a neighboring software analysis and services company, NoviSci, and scored an investment from California biotech pioneer Amgen.

Global biotherapeutics giant Grifols will soon start a clinical trial for what could become the second approved treatment for COVID-19.

Atsena Therapeutics is a Durham clinical-stage gene therapy company with $63M in the bank so far to propel its mission to reverse and prevent blindness.

A Jan. 28 virtual symposium, “BioGrow: Training and Education Across North Carolina,” is planned to get the word out to anyone interested in a career in biopharmaceuticals.

California gene therapy innovator Adverum Biotechnologies announced plans today to invest some $83 million to establish a manufacturing site in Durham that will employ 202 people through 2026.

Diana De Leon, an 18-year-old recent Pitt County high school grad, is proof that satisfying, rewarding, career-worthy jobs are waiting for a wide range of North Carolinians in the field of pharmaceutical manufacturing. She's now employed at Thermo Fisher Scientific in Greenville.

Ribometrix, a Durham company specializing in RNA-based therapeutics, has formed a drug discovery and development collaboration with Genentech that could be worth more than $1 billion.

Raleigh-based Marius Pharmaceuticals, led by several former GlaxoSmithKline scientists and executives, is making progress on its first potential drug.

Business Facilities magazine, a national publication serving corporate site selectors and economic development professionals, today proclaimed North Carolina the "2020 State of t

Durham's BioCryst Pharmaceuticals is developing its drug galidesivir as a potential treatment for more than 20 RNA viruses. SARS-CoV-2, the virus that causes COVID-19, will no longer be one of them.

Atox Bio, an Israeli company with U.S. headquarters in Durham, has received FDA acceptance of its new drug application for reltecimod, a drug developed for patients with necrotizing soft-tissue infections.

Xeomin, a botulinum toxin therapy developed by Raleigh-based Merz Therapeutics, has gained yet another new use.

Morrisville immunotherapies developer Heat Biologics is moving closer to human testing of a vaccine for COVID-19.

Dallas-based Taysha Gene Therapies announced plans today to invest $75 million in a gene therapy manufacturing facility in Durham that will employ 201 people over the next three years.

Aaron Lazarus, a Wake Forest University graduate who co-founded EncepHeal Therapeutics, a biotech company in Winston-Salem, has been recognized by Triad Business Journal’s “20 in their 20s” awards honoring young movers and shakers in the 12-county Triad region.